Treatment of Diabetes in Older Adults: An Endocrine Society

Derek Leroith; Geert Jan Biessels; Susan S. Braithwaite; Felipe F. Casanueva; Boris Draznin; Jeffrey B. Halter; Irl B. Hirsch; Marie E. Mcdonnell; Mark E. Molitch; M. Hassan Murad; Alan J. Sinclair

doi:10.1210/jc.2019-00198

Treatment of Diabetes in Older Adults: An Endocrine Society

Derek Leroith^*, Geert Jan Biessels, Susan S. Braithwaite, Felipe F. Casanueva, Boris Draznin, Jeffrey B. Halter, Irl B. Hirsch, Marie E. Mcdonnell, Mark E. Molitch, M. Hassan Murad, Alan J. Sinclair

^*Corresponding author for this work

Medicine, Endocrinology Division

Research output: Contribution to journal › Article › peer-review

371 Scopus citations

Abstract

Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

Original language	English (US)
Pages (from-to)	1520-1574
Number of pages	55
Journal	Journal of clinical endocrinology and metabolism
Volume	104
Issue number	5
DOIs	https://doi.org/10.1210/jc.2019-00198
State	Published - 2019

Funding

The guideline writing committee thanks the participating organizations and individuals with diabetes for their invaluable contribution to the patient voice in this guideline. We particularly thank the Reverend Albert Whitaker from the ADA’s Senior Signature program, Ronald H. Lammy from the Total Wellness for Elders Program at the Elder HealthCare Disparities Coalition (Roxbury, MA), and Sarah Mart from Diabetes Sisters. The writing committee thanks the cosponsors of this guideline for their contribution to the development effort. The Endocrine Society acknowledges that the American Geriatrics Society (AGS) affirms the value of this document. (Affirmation of value means that AGS supports the general principles in this document and believes it is of general benefit to its membership.) Financial Support: This guideline was supported by the Endocrine Society. No other entity provided financial support.

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1210/jc.2019-00198

Cite this

@article{4dc2b142376b4eb0935e00f78ea2d5f3,

title = "Treatment of Diabetes in Older Adults: An Endocrine Society",

abstract = "Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.",

author = "Derek Leroith and Biessels, {Geert Jan} and Braithwaite, {Susan S.} and Casanueva, {Felipe F.} and Boris Draznin and Halter, {Jeffrey B.} and Hirsch, {Irl B.} and Mcdonnell, {Marie E.} and Molitch, {Mark E.} and Murad, {M. Hassan} and Sinclair, {Alan J.}",

note = "Publisher Copyright: {\textcopyright} 2019 Endocrine Society.",

year = "2019",

doi = "10.1210/jc.2019-00198",

language = "English (US)",

volume = "104",

pages = "1520--1574",

journal = "Journal of clinical endocrinology and metabolism",

issn = "0021-972X",

publisher = "Endocrine Society",

number = "5",

}

TY - JOUR

T1 - Treatment of Diabetes in Older Adults

T2 - An Endocrine Society

AU - Leroith, Derek

AU - Biessels, Geert Jan

AU - Braithwaite, Susan S.

AU - Casanueva, Felipe F.

AU - Draznin, Boris

AU - Halter, Jeffrey B.

AU - Hirsch, Irl B.

AU - Mcdonnell, Marie E.

AU - Molitch, Mark E.

AU - Murad, M. Hassan

AU - Sinclair, Alan J.

PY - 2019

Y1 - 2019

N2 - Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

AB - Objective: The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions: Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85063923523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063923523&partnerID=8YFLogxK

U2 - 10.1210/jc.2019-00198

DO - 10.1210/jc.2019-00198

M3 - Article

C2 - 30903688

AN - SCOPUS:85063923523

SN - 0021-972X

VL - 104

SP - 1520

EP - 1574

JO - Journal of clinical endocrinology and metabolism

JF - Journal of clinical endocrinology and metabolism

IS - 5

ER -

Treatment of Diabetes in Older Adults: An Endocrine Society

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this